Open-Label, Single-Arm, Multiple-Dose Safety, Titration, And Pharmacokinetic Study Of AFREZZA® In Pediatric Subjects Ages 4 To 17 Years With Type 1 Diabetes Mellitus

Brief Description

The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.